A Study to Evaluate Solrikitug in Participants With COPD (ZION)

This is a Phase 2, randomized, placebo controlled, multiple dose ranging trial evaluating solrikitug in patients with COPD and elevated eosinophils. The trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics of two dose levels versus placebo over a 12 week treatment period.

Solrikitug is a monoclonal antibody that targets the Thymic Stromal Lymphopoietin (TSLP), a cytokine involved in initiating TH-2 inflammation, thereby preventing activation of downstream inflammatory cascades.

Primary End-Point:
  • Change from baseline in blood eosinophil counts at week 12
  • Change from baseline in FEV1
Solrikitug1
Key inclusion criteria are:
  • COPD with post-bronchodilator FEV₁ 40% - 80% predicted)
  • On dual or triple inhaled therapy for COPD
  • Eosinophil level 300-1500 k/µl
  • No Exacerbation History Required
ClinicalTrials.gov Identifier: NCT06496620

For more detailed information on this trial please click the link above to visit ClinicalTrials.gov

Thank You

For Contacting Us!

We’ll Respond to Your Message as Soon as Possible!